Neutrophil Activation and Hemostatic Changes in Healthy Donors Receiving Granulocyte Colony-Stimulating Factor

• Published in: Blood Vol. 93; no. 8; pp. 2506 - 2514
• Main Authors: Falanga, A., Marchetti, M., Evangelista, V., Manarini, S., Oldani, E., Giovanelli, S., Galbusera, M., Cerletti, C., Barbui, T.
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 15-04-1999; The Americain Society of Hematology
• Subjects: Adolescent; Adult; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Biological and medical sciences; Blood Donors; Bone marrow, stem cells transplantation. Graft versus host reaction; Child; Erythrocyte Count; Female; Filgrastim; Granulocyte Colony-Stimulating Factor - pharmacology; Hematocrit; Hematopoietic Stem Cells - drug effects; Hematopoietic Stem Cells - physiology; Hemoglobins - metabolism; Hemostasis - drug effects; Hemostasis - physiology; Humans; Leukocyte Count; Male; Medical sciences; Middle Aged; Neutrophil Activation - drug effects; Neutrophil Activation - physiology; Neutrophils - drug effects; Neutrophils - physiology; Platelet Count; Recombinant Proteins; Reference Values; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Human; Healthy subject; Stem cell; Cytokine; Homograft; Filgrastim; Chemotherapy; Granulocyte colony stimulating factor; Donor; Polypeptide; Graft; Biological effect; Progenitor cell
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V93.8.2506

Granulocyte colony-stimulating factor (G-CSF) enhances neutrophil functions in vitro and in vivo. It is known that neutrophil-derived products can alter the hemostatic balance. To understand whether polymorphonuclear leukocyte (PMN) activation, measured as PMN degranulation and phenotypical change, may be associated to hemostatic alterations in vivo, we have studied the effect of recombinant human G-CSF (rHuG-CSF) administration on leukocyte parameters and hemostatic variables in healthy donors of hematopoietic progenitor cells (HPCs). Twenty-six consecutive healthy donors receiving 10 μg/kg/d rHuG-CSF subcutaneously for 5 to 7 days to mobilize HPCs for allogeneic transplants were included in the study. All of them responded to rHuG-CSF with a significant white blood cell count increase. Blood samples were drawn before therapy on days 2 and 5 and 1 week after stopping rHuG-CSF treatment. The following parameters were evaluated: (1) PMN activation parameters, ie, surface CD11b/CD18 antigen expression, plasma elastase antigen levels and cellular elastase activity; (2) plasma markers of endothelium activation, ie, thrombomodulin (TM) and von Willebrand factor (vWF) antigens; (3) plasma markers of blood coagulation activation, ie, F1+2, TAT complex, D-dimer; and (4) mononuclear cell (MNC) procoagulant activity (PCA) expression. The results show that, after starting rHuG-CSF, an in vivo PMN activation occurred, as demonstrated by the significant increment of surface CD11b/CD18 and plasma elastase antigen levels. Moreover, PMN cellular elastase activity, which was significantly increased at 1 day of treatment, returned to baseline at day 5 to 6, in correspondence with the elastase antigen peak in the circulation. This change was accompanied by a parallel significant increase in plasma levels of the two endothelial and the three coagulation markers. The PCA generated in vitro by unstimulated MNC isolated from rHuG-CSF–treated subjects was not different from that of control cells from untreated subjects. However, endotoxin-stimulated MNC isolated from on-treatment individuals produced significantly more PCA compared with both baseline and control samples. All of the parameters were decreased or normal 1 week after stopping treatment. These data show that rHuG-CSF induces PMN activation and transiently affects some hemostatic variables in healthy HPC donor subjects. The clinical significance of these findings remains to be established.